Drug resistance characteristics of 
*Mycobacterium tuberculosis* isolates obtained between 2018 and 2020 in Sichuan, China

Ruifeng Zhou1, Tianli Zheng2,3,¶, Dongxia Luo1, Ma Zhu1, Qingfeng Li1, Yuanhong Xu1, Dongmei Wang1, Jia Luo1, Chongliang Zeng1, Guo Wei1, Mingyuan Tang2,3, Xing Zhao2,3, Mi Zhou1, Haojiang Zuo2,3 and Xiaofang Pei2,3

1Department of Clinical Laboratory, Chengdu Public Health Clinical Centre, Chengdu 610016, Sichuan Province, PR China; 2West China School of Public Health/West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China and 3Food Safety Monitoring and Risk Assessment Key Laboratory of Sichuan Province, Chengdu 610041, China

Abstract

We investigated the drug resistance of *Mycobacterium tuberculosis* isolates from patients with tuberculosis (TB) and HIV, and those diagnosed with only TB in Sichuan, China. TB isolates were obtained from January 2018 to December 2020 and subjected to drug susceptibility testing (DST) to 11 anti-TB drugs and to GeneXpert MTB/RIF testing. The overall proportion of drug-resistant TB (DR-TB) isolates was 32.1% (*n* = 10 946). HIV testing was not universally available for outpatient TB cases, only 29.5% (3227/10 946) cases had HIV testing results. The observed proportion of multidrug-resistant TB (MDR-TB) isolates was almost double than that of the national level, with approximately 1.5% and 0.1% of the isolates being extensively drug resistant and universally drug resistant, respectively. The proportions of resistant isolates were generally higher in 2018 and 2019 than in 2020. Furthermore, the sensitivities of GeneXpert during 2018–2020 demonstrated a downward trend (80.9, 95% confidence intervals (CI) 76.8–85.0; 80.2, 95% CI 76.4–84.1 and 75.4, 95% CI 70.7–80.2, respectively). Approximately 69.0% (7557/10 946) of the TB cases with DST results were subjected to GeneXpert detection. Overall, the DR-TB status and the use of GeneXpert in Sichuan have improved, but DR-TB challenges remain. HIV testing for all TB cases is recommended.

Introduction

Drug-resistant tuberculosis (DR-TB) remains a global issue and serious public health challenge. In 2019, the incidence of rifampicin-resistant TB was approximately 500 000 worldwide, with 78% of these cases being multidrug-resistant TB (MDR-TB) [1]. China ranked third globally, after India and Indonesia, in the number of TB cases in 2019 and also has the second highest global MDR-TB burden, accounting for 14% of the burden [1]. Furthermore, the prevalence of MDR-TB in this country varies regionally [2], at 13.3% in Sichuan [3], 9% in Beijing [4], 5% in Shanghai [5].

Sichuan is one of the most important provinces in Southwest China [6]. It comprises 21 regions and 183 counties, with a total area of 486 000 square kilometres. In 2020, the province had a recorded population of 83 million, ranked sixth (RMB 4859.88 billion) in total GDP and ranked first with an economic growth rate of 3.8% in China. Additionally, Sichuan has a high incidence of TB of approximately 100 cases per 100 000 people [7], with the second highest TB caseload among the provinces in China [8, 9]. Furthermore, the extensively drug-resistant (XDR)-TB notification rate significantly increased from 2010 to 2017 in Southwest China [10]. Approximately 9% of incident TB cases worldwide are among patients with HIV infection [11]. However, the characteristics of DR-TB isolates from patients with TB and HIV infection remain unclear in Sichuan. The GeneXpert assay is wildly applied for the rapid detection of TB in Sichuan. However, its detection rate and performance characteristics need to be updated.

In this study, we performed a comprehensive and updated retrospective investigation of the current drug resistance profiles of *M. tuberculosis* in the Sichuan core area from January 2018 to December 2020 and also analysed the local performance characteristics of the GeneXpert assay. This study is a continuation of our previous work [3].

Methods

Study setting

This study was conducted at the Chengdu Public Health Clinical Centre (https://www.phcc120.com/), which is the first and largest tertiary referral infectious disease specialist...
hospital, as well as the only officially designated medical institution for the treatment, research and prevention of TB in Sichuan. Overall, this hospital maintains the most comprehensive coverage of TB testing in China. This medical institution admits patients for TB hospital care, performs diagnostic evaluation of patients at high risk of MDR-TB, manages patients with various complications, and handles patients likely affected by TB. Moreover, this centre accepts TB samples from most hospitals, centres for disease control and prevention (CDCs), and health facilities in the province for drug susceptibility detection.

Patients who were diagnosed as being infected with TB [12] are admitted to the Jingju branch hospital of the Chengdu Public Health Clinical Centre. According to the requirements of the local health department, all TB strains isolated from TB patients in the core area of Sichuan should be sent to this hospital for drug susceptibility testing (DST), or patients should be directly transferred to this hospital for treatment and DST. Over 90% of TB cases in the core area of Sichuan are admitted here. Thus, this setting is a representative facility to reflect the status of TB drug resistance in Sichuan. The Clinical Laboratory of the Chengdu Public Health Clinical Centre has approximately 50 staff members and is divided into several professional groups, including a microbiology group, special mycobacterial group and molecular diagnostic group, with more than 300 tests on TB, AIDS and liver disease performed. This laboratory is also authorised to perform HIV screening and confirmation.

All admitted TB patients who stayed in the hospital while under treatment are required to receive HIV testing universally. Not all outpatient TB cases received HIV testing, because during 2018–2020, HIV testing is not mentioned as a necessary step for TB diagnosis at the country level [12]. According to the history of epidemiology, outpatients, who had multiple sex partners, history of intravenous drug use, or recurrent oral ulcers, etc., being suspected as HIV carriers, were subjected to HIV testing. The outpatient doctors also comprehensively judged whether patients with TB were at high risk of HIV infection, based on the symptoms, medical history and other related information. Testing was performed prior to TB diagnosis, with HIV infection confirmed by a combination of screening and antibody confirmation tests. The screening tests included enzyme-linked immunosorbent assay, a chemiluminescence assay, immunofluorescence assay and rapid test, and the antibody confirmation tests included western blotting, a line immunoblot assay and recombinant immunoblot assay. When screening and antibody confirmation tests did not confirm HIV in patients, PCR-based methods were applied [13, 14]. The patients with diagnosed HIV infection in this hospital could receive free antiretroviral therapy.

The routine detection procedure for TB was as follows. Patients suspected to have TB were diagnosed by hospital TB specialists, with two samples collected per patient. The samples were then subjected to M. tuberculosis culture (BD BACTEC MGIT 960 culture system; Sparks, MD, USA) and the GeneXpert (GeneXpert GX-XVI system; Cepheid, Sunnyvale, CA, USA) test, according to the manufacturers’ instructions. The GeneXpert test was optional and was performed at the patient’s expense. Drug sensitivity tests were conducted if the M. tuberculosis culture results were positive, regardless of the hospitalisation status of the patient. The treatment of MDR-TB was performed according to guidelines [15, 16].

Consecutive TB isolates were obtained from January 2018 to December 2020 and subjected to strain identification and DST. For patients with multiple isolates of one or more species, only the first isolate of each species was included in further analysis [17]. However, in patients with two TB isolates obtained from different samples, such as the sputum and bronchoscopy fluid, both isolates were subjected to DST. Non-tuberculous mycobacteria were excluded. TB isolates from patients with TB and HIV coinfection were included in the ‘TB_HIV group’. TB isolates from patients with negative HIV testing results and those at low risk of HIV infection being not subjected to HIV testing were included in the ‘general TB group’. The M. tuberculosis strains were stratified according to HIV infection status, patient age and calendar year of isolation for further analysis. Sample information, such as the patient’s age, sex, HIV status, strain isolation year, type of the species and strain identification results, were obtained from the Laboratory Information System of the Chengdu Public Health Clinical Centre.

**Mycobacterium tuberculosis culture and drug sensitivity testing**

The sputum, bronchoalveolar lavage fluid, pleural fluid, cerebrospinal fluid, ascites, pericardial effusion, gastric juice, secretions, pathological tissues, stools and urine were collected for mycobacterial culture. The confirmed M. tuberculosis isolates were then subjected to DST using DST kits purchased from Autobio Diagnostics Co., Ltd. (China Food and Drug Administration (CFDA) production licence 20160058; Zhengzhou, China) and Encode Medical Engineering Co., Ltd. (CFDA production licence 20010311; Zhuhai, China), according to the manufacturers’ instructions. The Autobio DST kits were used from January 2018 to January 2019, and the Encode DST kits were used from January 2019 to December 2020. The result evaluation system for para-aminosalicylic acid (PAS) was updated in October 2019.

Briefly, the sensitivities of isolates to anti-TB drugs (ATDs) were determined using a microplate dilution method with 7H9 broth media [3]. The inoculum size was set at 200 μl per well, with low and high optimised concentrations of each drug determined by the manufacturer based on the Clinical and Laboratory Standards Institute (CLSI) guidelines [18]. After 7 days of culture, contamination of the culture medium was evaluated. If no contamination was observed, the reading was performed after 12 or 13 days of culture. A total of 11 anti-TB drugs were tested at low and medium concentrations in two wells. The four first-line drugs included isoniazid (INH; 0.20 and 0.80 μg/ml), rifampicin (RIF; 4.0 and 8.0 μg/ml), streptomycin (STR; 4.0 and 8.0 μg/ml) and ethambutol (EMB; 2.5 and 5.0 μg/ml). The seven second-line drugs included the fluoroquinolone drugs levofloxacin (LFX; 2.0 and 8.0 μg/ml) and moxi-floxacin (MFX; 0.5 and 2.0 μg/ml); the injectable drugs amikacin (AMK; 1.0 and 4.0 μg/ml), kanamycin (KM; 2.5 and 10.0 μg/ml) and capreomycin (CM; 2.5 and 10.0 μg/ml). The M. tuberculosis standard strain H37Rv (ATCC 27294), which is susceptible to all ATDs, was used as the control in each round of testing. Interlaboratory confirmation tests were conducted for quality control.

**Definitions of drug resistance**

TB resistant to at least one of the four first-line and seven second-line drugs was defined as DR-TB. TB resistant to INH and RIF was defined as MDR-TB. TB resistant to INH, RIF, and either fluoroquinolones or a second-line anti-TB injectable drug (KM,
CM or AMK), but not to both, was defined as pre-XDR-TB. TB resistant to at least INH, RIF, any member of the quinolone family, and at least one second-line anti-TB injectable drug was defined as XDR-TB [3, 19].

**GeneXpert MTB/RIF assay**

The GeneXpert assay was conducted as previously described [3]. Briefly, 1 ml of each sample was added to 2 ml of the Xpert sample reagent, and the resulting solution was mixed for 1 min and digested at room temperature for 15 min with intermittent mixing. Subsequently, 2 ml of the sample solution was applied to the GeneXpert MTB/RIF GX-XVI system to determine the presence of *M. tuberculosis* and evaluate the resistance to RIF. Samples with unsuccessful GeneXpert results, including uncertain and failed results, were subjected to the second round of testing or excluded. The performance of the GeneXpert detection test was analysed for different samples (sputum, bronchoalveolar lavage fluid, pleural fluid, etc.). As the sample structure (proportion of different kinds of samples from 2018 to 2020) may have affected the sensitivity of the test, changes in the sample structure from 2018 to 2020 were further analysed.

**Statistical analysis**

Data were analysed using SPSS Statistics (version 19.0; SPSS Inc., Chicago, IL, USA) and RStudio (1.3.1093). Continuous variables are presented as the median and interquartile range (IQR). Comparisons among groups and between pairs were performed using the Kruskal–Wallis test and Dunn’s test, respectively. Categorical variables are presented as numbers and percentages and were analysed using the χ² test or Fisher’s exact test. The sensitivity (%), specificity (%), κ value, negative predictive value (NPV) and positive predictive value (PPV) of the GeneXpert assay were evaluated and compared with DST results for RIF [20]. Statistical significance was set at *P* < 0.05.

**Ethics statement**

This study was approved by the ethics committee of the Chengdu Public Health Clinical Centre. Patient personal information was not included in this study. Because of the retrospective nature of the study, the requirement for written informed consent was waived. All methods were used in accordance with the relevant guidelines and regulations of the Declaration of Helsinki.

**Results**

**Overall drug resistance patterns of TB isolates**

From January 2018 to December 2020, a total of 10 946 culture-confirmed TB isolates were reported. Among these, 6749 isolates were from the outpatient department, 3197 isolates were from the inpatient department, 945 isolates were from 20 health facilities (16 isolates from district/county CDCs, three isolates from hospitals and one isolate from a third-party medical testing centre), and 55 isolates were of unknown origin. In total, 120 of these isolates were obtained from patients confirmed with HIV coinfections by laboratory tests. Approximately 28.7% (3107/10 826) isolates from the general TB group contained HIV testing results (Supplementary file 1). Furthermore, 7067 isolates and 3759 isolates of the general TB group were from men and women, respectively, and 102 isolates and 18 isolates of the TB_HIV group were from men and women, respectively. Additionally, the men having TB isolates were significantly older than the women having TB isolates (median age: 44.0 (IQR: 26.0–59.0) vs. 30.0 (IQR: 23.0–48.0), *P* < 0.001). The frequency of TB and HIV coinfection was also higher in the men having TB isolates than in the women having TB isolates (1.46% vs. 0.48%, *P* < 0.001).

Among the *M. tuberculosis* isolates, the order of resistance to the 11 ATDs (sorted from high to low) was as follows: INH (21.0%), RIF (14.2%), STR (13.6%), RFB (9.1%), PAS (8.6%), MFX (7.3%), LFX (5.8%), EMB (4.9%), KM (3.7%), CM (3.4%) and AMK (2.5%). The isolates with single-drug resistance, first-line ATD resistance, second-line ATD resistance, multidrug resistance, extensive drug resistance and universal drug resistance comprised 32.1%, 25.5%, 20.7%, 12.2%, 1.5% and 0.1% of the strain pool, respectively. No significant differences in drug resistance characteristics were observed between the general TB and TB_HIV groups (Fisher’s exact test; Table 1).

**Sex-specific drug resistance profiles of TB isolates**

Isolates from the male general TB patients, compared with those from the female patients, had significantly higher proportions of INH resistance (21.8% vs. 19.4%, *P* = 0.004), any drug resistance (33.1% vs. 30.2%, *P* = 0.002), first-line drug resistance (26.3% vs. 23.9%, *P* = 0.007) and universal drug resistance (0.2% vs. 0.0%, *P* = 0.027) (Fisher’s exact test; Table 2). Comparison of the ATDs using the Kruskal–Wallis test showed no significant differences between the male and female groups.

**Age-specific drug resistance profiles of TB isolates**

The isolates were divided into the following five groups based on the age of the patients: <15, 15–24, 25–44, 45–64 and ≥65 years [1, 3]. Among these groups, the overall percentages of resistance to the 11 drugs, sorted from high to low, were as follows: 45–64 years, 35.6% (95% CI 33.9–37.3); 25–44 years, 33.2% (95% CI 31.6–34.7); 15–24 years, 30.2% (95% CI 28.4–32.1); ≥65 years, 27.9% (95% CI 25.7–30.0); and <15 years, 22.5% (95% CI 17.7–27.4) (Table 3). Apart from the resistance to CM, universal drug resistance and extensive drug resistance, resistances to ATDs among the five age-related groups of the TB isolates were significantly different (Fisher exact test, *P* < 0.05, Table 3). Similar results were also observed by comparing the groups associated with 45–64 and <15-year-old patients, as well as those associated with 25–44 and <15-year-old patients. When the data for the seven second-line ATDs were grouped together for the Kruskal–Wallis test, the group associated with 45–64-year-old patients showed significantly higher resistance than that associated with <15-year-old patients ($S = 16.143$, $P = 0.003$, adjusted $P = 0.032$, Dunn’s test). Notably, universal drug-resistant strains were isolated from all five subgroups (1, 1, 7, 4 and 2 isolates, respectively).

**Year-specific drug resistance profiles of TB isolates**

The isolates were divided into three groups according to the year of isolation. Among the groups, the percentages of drug resistance to the 11 drugs, sorted from high to low, were as follows: 2018 > 2019 > 2020 (Table 4). Apart from universal drug resistance, the resistances to ATDs were significantly different among the three
groups (Fisher’s exact test, \( P < 0.05 \), Table 4). Compared with the 2020 group, the 2018 and 2019 groups had higher percentages of resistance to RIF (12.4% vs. 15.7%, \( P < 0.001 \); 12.4% vs. 14.8%, \( P = 0.002 \), respectively), AMK (1.5% vs. 3.6%, \( P < 0.001 \); 1.5% vs. 2.6%, \( P = 0.001 \), respectively), CM (1.5% vs. 3.1%, \( P < 0.001 \); 1.5% vs. 5.4%, \( P < 0.001 \), respectively), MFX (5.1% vs. 11.0%, \( P < 0.001 \); 5.1% vs. 6.7%, \( P = 0.002 \), respectively), any drugs (26.2% vs. 31.1%, \( P < 0.001 \); 26.2% vs. 38.2%, \( P < 0.001 \), respectively), any second-line drugs (13.5% vs. 19.2%, \( P < 0.001 \); 13.5% vs. 28.3%, \( P = 0.002 \), respectively) and multidrugs (10.6% vs. 14.3%, \( P < 0.001 \); 10.6% vs. 12.2%, \( P = 0.029 \), respectively). By contrast, the 2020 group had relatively lower percentages of XDR isolates than those in the 2018 and 2019 groups (0.8% vs. 2.7%, \( P = 0.007 \); 0.8% vs. 1.1%, \( P = 0.216 \), respectively).

**Table 1.** Drug resistance patterns of *Mycobacterium tuberculosis* isolates (\( n = 10\ 946 \))

| Drug resistance | General TB (%(95%CI)) (\( n = 10\ 826 \)) | TB_HIV (%(95%CI)) (\( n = 120 \)) |
|-----------------|------------------------------------------|----------------------------------|
| INH             | 21.0%(20.2–21.8)                         | 19.2%(12.1–26.2)                 |
| STR             | 13.6%(13.0–14.2)                         | 10.8%(5.2–16.4)                  |
| Rif             | 14.2%(13.6–14.9)                         | 10.8%(5.2–16.4)                  |
| EMB             | 4.9%(4.5–5.3)                            | 6.7%(2.2–11.1)                   |
| RFB             | 9.1%(8.6–9.6)                            | 7.5%(2.8–12.2)                   |
| AMK             | 2.5%(2.2–2.8)                            | 3.3%(0.1–6.6)                    |
| CM              | 3.4%(3.1–3.8)                            | 2.5%(0.0–5.3)                    |
| KM              | 3.7%(3.3–4.1)                            | 5.0%(1.1–8.9)                    |
| LFX             | 5.8%(5.4–6.2)                            | 3.3%(0.1–6.6)                    |
| MFX             | 7.3%(6.8–7.8)                            | 5.8%(1.6–10.0)                   |
| PAS             | 8.6%(8.1–9.1)                            | 8.3%(3.4–13.3)                   |
| Any drug resistance\* | 32.2%(31.3–33.1)                         | 25.8%(18.0–33.7)                 |
| First-line drug resistance | 25.5%(24.7–26.3) | 22.5%(15.0–30.0) |
| Second-line drug resistance | 20.8%(20.0–21.5) | 16.7%(10.0–23.4) |
| Universal drug resistance\* | 0.1%(0.1–0.2) | 0.0%( –) |
| MDR             | 12.3%(11.7–12.9)                         | 9.2%(4.0–14.4)                   |
| Pre-XDR         | 4.0%(3.6–4.4)                            | 2.5%(0.0–5.3)                    |
| XDR             | 1.5%(1.3–1.7)                            | 1.7%(0.4–4.0)                    |
| INH + STR       | 10.9%(10.3–11.5)                         | 9.2%(4.0–14.4)                   |
| INH + EMB       | 4.6%(4.2–5.0)                            | 5.8%(1.6–10.0)                   |
| INH + Rif + STR | 7.5%(7.0–8.0)                            | 6.7%(2.2–11.1)                   |
| INH + Rif + EMB | 3.7%(3.3–4.0)                            | 4.2%(0.6–7.8)                    |
| INH + Rif + STR + EMB | 2.7%(2.4–3.0) | 2.5%(0.0–5.3) |

\*Resistant to at least one drug.

**Table 2.** Sex-specific distribution of drug-resistant *Mycobacterium tuberculosis* isolates (\( n = 10\ 946 \))

| Drug resistance | Male TB patients (%(95%CI)) (\( n = 7169 \)) | Female TB patients (%(95%CI)) (\( n = 3777 \)) |
|-----------------|---------------------------------------------|-------------------------------------------------|
| INH             | 21.8%(20.8–22.7)                            | 19.4%(18.2–20.7)                               |
| STR             | 13.9%(13.1–14.7)                            | 13.0%(11.9–14.0)                               |
| Rif             | 14.5%(13.7–15.4)                            | 13.6%(12.5–14.7)                               |
| EMB             | 5.1%(4.6–5.6)                               | 4.6%(3.9–5.2)                                  |
| RFB             | 9.4%(8.7–10.0)                               | 8.6%(7.7–9.4)                                  |
| AMK             | 2.5%(2.2–2.9)                               | 2.4%(1.9–2.9)                                  |
| CM              | 3.4%(3.0–3.8)                               | 3.4%(2.8–4.0)                                  |
| KM              | 4.0%(3.4–4.4)                               | 3.3%(2.7–3.8)                                  |
| LFX             | 5.9%(5.3–6.4)                               | 5.5%(4.8–6.3)                                  |
| MFX             | 7.5%(6.9–8.1)                               | 7.0%(6.2–7.8)                                  |
| PAS             | 8.8%(8.2–9.5)                               | 8.2%(7.4–9.1)                                  |
| Any drug resistance\* | 33.1%(32.0–34.2) | 30.2%(28.7–31.7) |
| First-line drug resistance\* | 26.3%(25.3–27.3) | 23.9%(22.5–25.3) |
| Second-line drug resistance | 21.2%(20.3–22.2) | 19.8%(18.5–21.0) |
| Universal drug resistance\* | 0.2%(0.1–0.3) | 0.0%(0.0–0.1) |
| MDR             | 12.6%(11.8–13.4)                            | 11.6%(10.5–12.6)                               |
| Pre-XDR         | 4.1%(3.6–4.5)                               | 3.8%(3.2–4.4)                                  |
| XDR             | 1.5%(1.2–1.7)                               | 1.5%(1.1–1.9)                                  |
| INH + STR       | 11.0%(10.3–11.8)                            | 10.5%(9.5–11.5)                                |
| INH + EMB       | 4.8%(4.3–5.3)                               | 4.3%(3.6–4.9)                                  |
| INH + Rif + STR | 7.8%(7.2–8.4)                               | 7.0%(6.2–7.9)                                  |
| INH + Rif + EMB | 3.9%(3.5–4.4)                               | 3.3%(2.7–3.8)                                  |
| INH + Rif + STR + EMB | 2.9%(2.5–3.2) | 2.4%(1.9–2.9) |

\*Resistant to at least one drug.

**Performance characteristics of the GeneXpert assay**

From 2018 to 2020, 7586 samples were subjected to GeneXpert detection and drug sensitivity testing, of which 2486 (five uncertain results and three subjected to the second round of testing with successful results), 2797 (13 uncertain results and two subjected to the second round of testing with successful results) and 2303 (21 uncertain results and five subjected to the second round of testing with successful results) samples were tested in 2018, 2019 and 2020, respectively. The 10 samples with uncertain results that were subjected to the second round of testing were included in further data analysis, while the 29 samples that were not subjected to the second round of testing were excluded. No significant differences in the success rates were observed between sputum and other samples (99.45% (6100/6134) vs. 99.66% (1447/1452), \( P > 0.05 \)).
Approximately 69.0% (7557/10946) of the isolates had both DST and successful GeneXpert assay results. For RIF resistance testing of the *M. tuberculosis* isolates, we observed a sensitivity of 79.0% (95% CI 76.6–81.4), specificity of 95.9% (95% CI 95.5–96.4), PPV of 76.7 (95% CI 74.2–79.2), NPV of 96.4 (95% CI 96.0–96.9) and κ value of 0.741 (95% CI 0.73–0.752). Similar results were obtained for the general TB group (Table 5). The sensitivity and specificity of the GeneXpert test for the strains from the TB HIV group were 80.4% (95% CI 78.0–82.9) and 96.2% (95% CI 95.7–96.7), respectively (Table 5). The PPV, NPV and κ values for the TB HIV group were 78.0% (95% CI 75.5–80.6), 96.7% (95% CI 96.2–97.1) and 0.584 (95% CI 0.451–0.717), respectively (Table 5). The sensitivities for the three consecutive year groups (2018, 2019 and 2020) demonstrated a downward trend (80.9 (95% CI 76.8–85.0) vs. 80.2 (95% CI 76.4–84.1) vs. 75.4 (95% CI 70.7–80.2), respectively; Table S1).

Regarding the GeneXpert sensitivity of different samples, the highest sensitivity (84.2%) was obtained with bronchoalveolar lavage and pleural fluids, the second highest sensitivity (79.0%) was obtained with sputum samples, and the lowest sensitivity (65.5%) was obtained with the other samples (Table S2). Additionally, the GeneXpert test showed statistically different sensitivity results for the three types of samples (χ² = 9.045, P = 0.011). Furthermore, no significant changes in the sample structure were observed among the different year groups (Table S3).

**Discussion**

This study revealed the drug resistance profiles of *M. tuberculosis* isolates from patients with TB in Sichuan, China, from January 2018 to December 2020. Generally, the DR-TB status improved annually. The overall proportion of DR-TB among culture-confirmed TB was 32.1% (3514/10946). This result was similar to the proportion reported in a previous study conducted in Chinese Jiangxi (33.1% (352/1063)) [21] and Chinese Dalian (31.1% (1106/3552)) [22], but higher than those reported for Central China (14.8% (531/3580)), Eastern China (12.8% (185/1497)), and some regions of China [23].
14 7757)) and Western China (10.8% (1198/11 097)) [23] and lower than that found in our previous study, which was conducted from 2014 to 2017 (52.7% (3933/7470)) [3]. Similar results were also obtained for MDR-TB. The overall proportion of MDR-TB among culture-confirmed TB was 12.2% (1340/10 946), which was similar to those in Chinese Jiangxi (14.8% (157/1063)) [21], Eastern China (12.8% (2967/32 707)) [23] and Western China (12.3% (1957/15 929)) [23], as well as in our previous 2014–2017 study (14.6% (1088/7470)) [3]. However, the proportion was higher than those in Chinese Dalian (10.1% (359/3552)) [22], Central China (8.5% (501/5899)). By contrast, the overall proportion of XDR-TB in this study was 1.5% (162/10 946), which was similar to those in Jiangxi (2.4% (26/1063)) [21], Dalian (2.1% (75/3552)) [22] and Sichuan from 2014 to 2017 (1.4% (103/7470)) [3]. These findings indicated that while the DR-TB status in Sichuan remains serious, the situation has improved.

Meanwhile, in our study, approximately 1.1–3.7% (120/10 826 to 120/3227) of the incident TB cases were among patients with HIV infection, which was notably lower than the worldwide proportion of 9% [11], the Mainland China proportion of 7.4% [24] and the China proportion of 7.3% released by WHO [25, 26]. The potential reasons for the discrepancies between our reported number and that at the country level as presented by other reports [24–26] might be because of the different data sources. Some data are from routine surveillance of TB. While, some data sources are from non-routine surveillance of HIV prevalence in TB patients [26]. And due to the retrospective nature, we could not possibly better explain those reasons. Indeed, in our study, some TB-HIV patients could be missed because of the low proportion of HIV testing for TB patients. The extended unavailability of HIV testing for the general TB group might be due to the HIV testing being optional for TB patients. WHO has recommended HIV testing for all TB patients for a long time [27]. Our tertiary referral infectious disease hospitals and related health facilities could consider a full HIV screening coverage strategy for all TB patients according to the requirement of WHO. It could not only help to find more TB-HIV patients for early disease control but also decrease the discrepancies of TB-HIV incidence at the country level from different reports [24–26]. Our work brings attention to the prevalence of MDR-, XDR- and universal DR-TB infections, as well as to the low proportion of HIV testing for outpatient TB cases in Southwest China.

With respect to the age, the 45–64- and 25–44-year-old groups had the highest proportions of MDR-TB, which were significantly

| Drug resistance | 2018 (%(95%CI)) (n = 2989) | 2019 (%(95%CI)) (n = 4184) | 2020 (%(95%CI)) (n = 3773) | P values* |
|-----------------|--------------------------|--------------------------|--------------------------|----------|
| INH             | 23.9%(22.4–25.5)         | 20.4%(19.2–21.6)         | 19.3%(18.0–20.6)         | <0.001   |
| STR             | 15.9%(14.6–17.2)         | 12.1%(11.1–13.1)         | 13.3%(12.2–14.4)         | <0.001   |
| RIF             | 15.7%(14.4–17.0)         | 14.8%(13.7–15.9)         | 12.4%(11.3–13.4)         | <0.001   |
| EMB             | 10.7%(9.6–11.8)          | 2.0%(1.6–2.4)            | 3.6%(3.0–4.1)            | <0.001   |
| RFB             | 13.0%(11.8–14.2)         | 8.1%(7.3–8.9)            | 7.1%(6.3–7.9)            | <0.001   |
| AMK             | 3.6%(2.9–4.2)            | 2.6%(2.1–3.0)            | 1.5%(1.1–1.9)            | <0.001   |
| CM              | 3.1%(2.5–3.7)            | 5.4%(4.7–6.1)            | 1.5%(1.1–1.9)            | <0.001   |
| KM              | 1.7%(1.2–2.1)            | 6.5%(5.7–7.2)            | 2.3%(1.8–2.8)            | <0.001   |
| LFX             | 9.3%(8.3–10.3)           | 4.8%(4.2–5.5)            | 4.0%(3.4–4.6)            | <0.001   |
| MFX             | 11.0%(9.9–12.1)          | 6.7%(5.9–7.4)            | 5.1%(4.4–5.8)            | <0.001   |
| PAS             | 3.2%(2.5–3.8)            | 15.9%(14.8–17.0)         | 4.9%(4.2–5.5)            | <0.001   |
| Any drug resistancea | 31.1%(29.4–32.7)       | 38.2%(36.7–39.6)         | 26.2%(24.8–27.6)         | <0.001   |
| First-line drug resistance | 27.9%(26.3–29.5)    | 25.1%(23.8–26.4)         | 23.9%(22.5–25.3)         | = 0.001  |
| Second-line drug resistance | 19.2%(17.8–20.6)  | 28.3%(26.9–29.7)         | 13.5%(12.5–14.6)         | <0.001   |
| Universal drug resistancec | 0.2%(0.0–0.4)   | 0.0%(0.0–0.1)            | 0.2%(0.0–0.3)            | = 0.109  |
| MDR             | 14.3%(13.1–15.6)         | 12.2%(11.2–13.2)         | 10.6%(9.6–11.6)          | <0.001   |
| Pre-XDR         | 5.8%(5.0–6.6)            | 3.6%(3.0–4.1)            | 3.0%(2.4–3.5)            | <0.001   |
| XDR             | 2.7%(2.2–3.3)            | 1.1%(0.8–1.5)            | 0.8%(0.6–1.1)            | <0.001   |
| INH + STR       | 13.4%(12.2–14.7)         | 9.6%(8.9–10.7)           | 10.0%(9.1–11.0)          | <0.001   |
| INH + EMB       | 9.9%(8.9–11.0)           | 1.9%(1.5–2.3)            | 3.4%(2.9–4.0)            | <0.001   |
| INH + RIF + STR | 9.2%(8.2–10.2)           | 6.7%(5.9–7.4)            | 7.1%(6.3–8.0)            | <0.001   |
| INH + RIF + EMB | 8.1%(7.1–9.1)            | 1.3%(1.0–1.7)            | 2.8%(2.3–3.3)            | <0.001   |
| INH + RIF + STR + EMB | 6.2%(5.3–7.0) | 0.7%(0.4–0.9)            | 2.2%(1.8–2.7)            | <0.001   |

TB, tuberculosis; HIV, human immunodeficiency virus; DST, drug sensitivity testing; 95% CI, 95% confidence intervals; INH, isoniazid; STR, streptomycin; RIF, rifampicin; EMB, ethambutol; LFX, levofloxacin; AMK, amikacin; CM, capreomycin; MFX, moxifloxacin; PAS para-aminosalicylic acid; RFB, rifabutin; KM, kanamycin; MDR, multidrug-resistant; XDR, extensively drug-resistant.
aResistant to at least one drug.
bResistant to all 11 drugs involved in drug susceptibility testing.
higher than that in the <15-year-old group (14.7% and 13.0% vs. 6.0%, respectively). In addition, the 25–44-year-old group had a significantly higher XDR-TB proportion than those in the <15-year-old (2.1% vs. 0.4%) and 15–24-year-old (2.1% vs. 0.8%) groups. These results indicate that the patients with TB in the 25–64 years of age group, which consists of the majority of the labour force, are still at high risk for the development of MDR- and XDR-TB. Recent global estimates also show a considerable TB burden among young adults, which leads to unique challenges in effective diagnosis and treatment [28]. Meanwhile, it has been reported that the 25–44 years of age group is the most affected group, with the highest incidence rate of RIF-resistant TB [29]. Thus, more attention should be focused on this group of patients.

Regarding the different study years, the overall TB drug resistance status gradually improved from 2018 to 2020. Our results demonstrated a continuous improvement in overall control of TB drug resistance in Sichuan over the past 3 years, a finding consistent with that of a previous study [3]. Currently, TB treatment in China is reimbursable through medical insurance, with a basic medical insurance coverage rate of 96.8% [30]. Meanwhile, support from overseas groups, such as the Bill & Melinda Gates Foundation, aids in the development of programmes to strengthen TB control [31], which may have contributed to the observed annual improvement of the TB drug resistance status.

The MDR- and XDR-TB cases decreased annually from 2018 in China were 92% and 98%, respectively [34]. However, recent data from Sichuan Province were not included in this systematic review. Furthermore, only one study on TB in Sichuan was conducted with a relatively small sample size (n = 268) of isolates from January 2008 to May 2010 [35]. Our findings demonstrated a lower sensitivity but steadier specificity (81.1% and 94.6%, for 2014–2017 [3] and 79.5% and 96.0%, for 2018–2020) than the findings of the above-mentioned systematic review [34]. The observed sensitivities in our studies were comparable to those in the United States (81.0%) [36] and Morocco (78.8%) [37].

Table 5. Performance characteristics of the GeneXpert assay compared to drug susceptibility testing for rifampicin between the general TB and TB_HIV groups (n = 7557)

| Xpert MTB/RIF | DST-RIF |     |     |     |     |
|---------------|---------|-----|-----|-----|-----|
|               | resistant | sensitive | Total | PPV (%(95%CI)) | NPV (%(95%CI)) |
| 2018–2020, general TB (n = 7470) |         |     |     |     |     |
| GX-RIF(+)     | 851     | 256 | 1107 | 76.8(74.3–79.3) |     |
| GX-RIF(–)     | 223     | 6140| 6363| 96.4(96.0–96.9) |     |
| Total         | 1074    | 6396| 7470|     |     |
| Sensitivity(%(95%CI)) | 79.2(76.8–81.6) |     |     |     |     |
| Specificity(%(95%CI)) | 95.9(95.5–96.4) |     |     |     |     |
| κ(95%CI)      | 0.743(0.732–0.754) |     |     |     |     |
| 2018–2020, TB_HIV (n = 87) |         |     |     |     |     |
| GX-RIF(+)     | 7       | 4   | 11  | 78.0(75.5–80.6) |     |
| GX-RIF(–)     | 4       | 72  | 76  | 96.7(96.2–97.1) |     |
| Total         | 11      | 76  | 87  |     |     |
| Sensitivity(%(95%CI)) | 80.4(78.0–82.9) |     |     |     |     |
| Specificity(%(95%CI)) | 96.2(95.7–96.7) |     |     |     |     |
| κ(95%CI)      | 0.584(0.451–0.717) |     |     |     |     |

DST, drug susceptibility testing; MTB, Mycobacterium tuberculosis; GX, GeneXpert; RIF, rifampicin; 95% CI, 95% confidence interval; NPV, negative predictive value; PPV, positive predictive value.
The sensitivities of the GeneXpert assay were not significantly different in 2018, 2019 and 2020 (80.9%, 80.2% and 75.4%, respectively; Table S1). However, the sensitivities showed a downward trend during the three consecutive years. Since the Xpert buffer was designed for sputum samples, application of this method to other specimens may have affected the outcome by increasing false-negative results and decreasing overall sensitivity [38]. In our study, no significant difference in the success rate between sputum and other samples (99.45% vs. 99.66%) was observed. Meanwhile, we found that GeneXpert was the most sensitive with bronchoalveolar lavage and plural fluids (mainly pulmonary TB) and the least sensitive with other samples (mainly extrapulmonary TB; Table S2). Similar results have also been reported in a recent multicentre study [38]. Regarding the effect of the sample structure on GeneXpert performance, no significant changes in the sample structure were observed among the different years. However, the proportions of bronchoalveolar lavage and plural fluid samples, for which the test showed the highest sensitivity, gradually decreased from 14.95% in 2018 to 13.20% in 2020. The proportions of other samples also decreased from 5.90% in 2018 to 4.80% in 2020. These data suggest that the sample structure has little effect on the sensitivity of GeneXpert. Thus, we speculated that some TB cases might be caused by new mutants, which are not recognised by the five rpoB molecular beacons used in the GeneXpert assay [39]. The new and inexpensive GeneXpert MTB/RIF Ultra assay and gene sequencing-based detection may be highly accurate potential options [36, 40]. In addition, guaranteeing the quality of sample collection and preparation for the GeneXpert test may aid in maximising its performance for MDR-TB control. For example, strict collection of morning sputum samples and avoidance of saliva may increase the positivity rate of GeneXpert testing.

The limitations of our study are as follows. First, the information about new and previously treated TB cases, medication details and drug side effects was not available. Second, HIV testing was not universally available for all outpatient TB cases, 71.3% of the individuals in the general TB group did not have HIV testing results, thus potentially leading to misclassification of patients in the general TB group. Third, we did not collect TB data from all DCs, hospitals and healthcare facilities in Sichuan. Fourth, not all types of ATDs were included, and not all isolates were submitted to GeneXpert testing. These limitations might have resulted in an inaccurate evaluation of the overall TB status in Sichuan Province. Thus, more comprehensive collection of information from databases of patients with TB from multiple centres is required for future studies.

Conclusion

This study summarises the status of ATD resistance in patients with TB in Sichuan, China, from January 2018 to December 2020. Our findings indicate a decreasing trend in overall ATD resistance of TB isolates from 2018 to 2020. No significant differences were observed in drug resistance characteristics between the general TB and TB, HIV groups. However, MDR-TB remains severe, especially among middle-aged patients. The increased usage rate of GeneXpert, and guaranteeing the quality of sample collection and preparation for GeneXpert testing may aid in maximising the test performance for MDR-TB control. However, the gradual decrease in the sensitivity of the GeneXpert assay should be noticed. And HIV testing for each outpatient TB case is recommended for early treatment and management.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0950268822000127

Acknowledgments. The data were analysed at the Public Health and Preventive Medicine Provincial Experiment Teaching Centre at Sichuan University and the Food Safety Monitoring and Risk Assessment Key Laboratory of Sichuan Province.

Author contributions. RFZ, TLZ, HJZ, MZ and XZ conceived and designed the experiments. RFZ, DXL, MZ, QFL, YHX, DMW, JL, CLZ and WG performed the experiments. HJZ and MYT analysed the data. HJZ, MZ and TLZ wrote the main manuscript text. All authors reviewed the manuscript and agreed to submit the manuscript for publication.

Financial support. This work was supported by the National Key Research and Development Program of China (Xin Zhao, grant number 2017YFC0907305, 2017YFC0907300), the Chinese National Science and Technology Major Project’s 13th Five-Year Plan: Technical Platform for Communicable Disease Surveillance Project (Zheng, grant number 2017ZX1003010–002), the Health and Family Planning Commission of Sichuan Province (Mi Zhou, grant number 18PJ392), the Chengdu Municipal Commission of Health and Family Planning (Mi Zhou, grant number 2015149), the Department of Science and Technology of Sichuan Province (Haojiang Zuo, grant number 2019YJ0018), the Chengdu Science and Technology Bureau (Haojiang Zuo, grant number 2019-YF05-01247-SN), the Yibin Science and Technology Bureau (Haojiang Zuo, grant number 2021NY006). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest. None.

Data availability statement. The data that support the findings of this study are openly available. Please find the datasets in Supplementary file 1.

References

1. WHO (2020) Global Tuberculosis Report 2020. CC BY-NC-SA 3.0 IGO ed. Geneva: World Health Organization.
2. Wu X et al. (2019) Drug resistance characteristics of Mycobacterium tuberculosis isolates from patients with Tuberculosis to 12 antituberculous drugs in China. Frontiers in Cellular and Infection Microbiology 9, 345.
3. Zhou M et al. (2018) Drug resistance characteristics of Mycobacterium tuberculosis isolates between 2014 and 2017 in Sichuan, China: a retrospective study. PLoS ONE 13, e0209902.
4. Liu Y et al. (2018) Characterization of Mycobacterium tuberculosis strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission. BMC Infectious Diseases 18, 658.
5. Yang C et al. (2017) Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. The Lancet Infectious Diseases 17, 275–284.
6. Zuo HJ et al. (2020) Study on the salivary microbial alteration of men with head and neck cancer and its relationship with symptoms in Southwest China. Frontiers in Cellular and Infection Microbiology 10, 514943.
7. Yang XY et al. (2008) Epidemiological analysis of pulmonary tuberculosis in Sichuan Province, China, 2000–2006. International Journal of Infectious Diseases 12, 534–541.
8. The People’s Government of Sichuan Province (2020) Population and employment. In. Sichuan, China. Available at https://www.scm.gov.cn/10462/wza2012/scgk/scgk.shtml (Accessed 14 October 2021).
9. Wang D-M et al. (2020) Epidemiological, clinical characteristics and drug resistance situation of culture-confirmed children TBM in southwest of China: a 6-year retrospective study. BMC Infectious Diseases 20, 318.
10. Wu B et al. (2019) Epidemiology of drug-resistant tuberculosis in Chongqing, China: a retrospective observational study from 2010 to 2017. PLoS ONE 14, e0216018.
11. Saldhana N et al. (2019) High prevalence of multi drug resistant tuberculosis in people living with HIV in Western India. BMC Infectious Diseases 19, 391.

https://doi.org/10.1017/S0950268822000127 Published online by Cambridge University Press
12. Prevention CCfDCa (2017) Diagnosis for pulmonary tuberculosis (WS 288-2017). In. Beijing, China. Available at http://www.nhc.gov.cn/wjw/s9491/201712/a452586fd21d4018b0ebc00fb89c0e254.shtml (Accessed 12 December 2017).

13. Prevention CCfDCa (2015) National guideline for detection of HIV/AIDS (Revised in 2015). In. Beijing, China. Available at http://www.chinacdc.cn/gwswxx/xzxx/201608/2016080810_133531.html (Accessed 10 August 2016).

14. Prevention CCfDCa (2020) National guideline for detection of HIV/AIDS (Revised in 2020). In. Beijing, China. Available at http://ncacdc.chinacdc.cn/xsggj/sj/202005/n20200518_216798.htm (Accessed 18 May 2020).

15. WHO (2018) Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). In. Geneva, Switzerland. Available at https://apps.who.int/iris/handle/10665/275383. License: CC BY-NC-SA 3.0 IGO.

16. China Anti-tuberculosis Association (2019) Guidelines for chemotherapy of drug resistant tuberculosis. Chinese Journal of Antituberculosis 41, 1025–1073.

17. Zhang H et al. (2020) Species identification and antimicrobial susceptibility testing of non-tuberculous mycobacteria isolated in Chongqing, Southwest China. Epidemiology and Infection 149, e7.

18. Wayne PA (2008) Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed CLSI document M23-A3. In: Clinical and Laboratory Standards Institute: Clinical and Laboratory Standards Institute.

19. Wang J et al. (2020) Survival of patients with multidrug-resistant tuberculosis in Central China: a retrospective cohort study. Epidemiology and Infection 148, e50.

20. Tang T et al. (2017) Evaluation of GeneXpert MTB/RIF for detecting Mycobacterium tuberculosis in a hospital in China. Journal of International Medical Research 45, 816–822.

21. Luo D et al. (2019) Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China. Scientific Reports 9, 7315.

22. Lv XT et al. (2017) Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China. Journal of International Medical Research 45, 1779–1786.

23. Duan Q et al. (2016) The prevalence of drug-resistant tuberculosis in Mainland China: an updated systematic review and meta-analysis. PLoS ONE 11, e0148041.

24. Gao L et al. (2010) HIV/TB co-infection in mainland China: a meta-analysis. PLoS ONE 5, e10736.

25. WHO. Global Tuberculosis Report 2013. In, 2015. Available at http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf (Accessed 10 April 2015).

26. WHO. The 2021 edition of the Global Tuberculosis Report. In, 2021. Available at https://www.who.int/teams/global-tuberculosis-programme/data (Accessed 14 October 2021).

27. Nliwasa M et al. (2018) High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses. Journal of the International AIDS Society 21, e25162.

28. Snow KJ et al. (2018) The incidence of tuberculosis among adolescents and young adults: a global estimate. European Respiratory Journal 51, 1702352.

29. Bahizi G et al. (2021) Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014–2018. Antimicrobial Resistance and Infection Control 10, 76.

30. PRC NHCoT (2021) The Sixth National Health Service Statistical Survey Report. In. Beijing, China. Available at http://www.nhc.gov.cn/mohwsbwstjxxzx/a2908/202101/0838723e3f3a4adb835d970abdd51665.shtml (Accessed 27 January 2021).

31. Long Q et al. (2021) Scale-up of a comprehensive model to improve tuberculosis control in China: lessons learned and the way forward. Infectious Diseases of Poverty 10, 41.

32. Zhou M et al. (2021) A preliminary study of antibodies and antigen kinetics in patients with COVID-19. Research Square Preprint, 1–8.

33. Chen H and Zhang K (2020) Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China. European Respiratory Journal 56, 2002710.

34. Sun Y et al. (2019) Accuracy of molecular diagnostic tests for drug-resistant tuberculosis detection in China: a systematic review. International Journal of Tuberculosis and Lung Disease 23, 931–942.

35. Tang K et al. (2013) Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. Tuberculosis (Edinb) 93, 89–95.

36. Chakravorty S et al. (2017) The New Xpert MTB/RIF ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8, e00812-17.

37. Mechal Y et al. (2019) Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis. BMC Infectious Diseases 19, 1069.

38. Allahyartorkaman M et al. (2019) Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: a multicenter surveillance. Scientific Reports 9, 18515.

39. Singh UB et al. (2016) Genotypic, phenotypic and clinical validation of GeneXpert in extra-pulmonary and pulmonary tuberculosis in India. PLoS ONE 11, e0149258.

40. Chen X et al. (2019) Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistance Mycobacterium tuberculosis isolates from China. Frontiers in Microbiology 10, 174i.